Effect of Low Versus Standard Dialysate Sodium on 48h Ambulatory BP in Patients With Intradialytic Hypertension
NCT05430438 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2024-10-16
Summary
Intradialytic hypertension (IDH) is a well-recognized and established complication of hemodialysis that affects an estimated 10-15% of the dialysis population and is associated with an increased risk for cardiovascular adverse events and mortality. The major pathogenic mechanisms include volume and sodium overload, endothelial dysfunction and enhanced vasoconstriction potentially through the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) activation. Preliminary uncontrolled studies have demonstrated that in order to achieve proper control of blood pressure (BP) in patients with IDH, volume control with achievement of dry weight, as well as the minimization of sodium load through alteration of dialysate sodium may improve BP. To this day, 3 studies have attempted to evaluate the effect of low dialysate sodium on BP levels in patients with IDH; one study that included 16 patients, compared the effect of low (5 milliequivalent/litre (mEq/L) lower than serum sodium) versus high (5 mEq/L higher than serum sodium) dialysate sodium concentration on BP levels only during the dialysis session; another study examined the effect of low (136 mEq/L) compared to standard (140 mEq/L) sodium dialysate, again, only on peridialytic and intradialytic BP; and only one randomized cross-over study used 24h ABPM to assess the effect of individualized isonatremic vs hyponatremic vs standard dialysate sodium. Hence, the aim of this study is to examine the effect of low (137mEq/L) vs standard (140mEq/L) dialysate sodium on 48h ambulatory blood pressure monitoring (ABPM) in patients with IDH, using appropriate design of randomized crossover study. In addition this is the first study examining the effect of low dialysate sodium on ambulatory central BP, arterial stiffness indices and BP variability in patients with IDH.
Conditions
- Intradialytic Hypertension
- End Stage Kidney Disease
Interventions
- OTHER
-
dialysis with low dialysate sodium concentration
Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
- OTHER
-
dialysis with standard dialysate sodium concentration
Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
Sponsors & Collaborators
-
Aristotle University Of Thessaloniki
lead OTHER
Principal Investigators
-
Pantelis Sarafidis, Prof · Aristotle University Of Thessaloniki
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-01
- Primary Completion
- 2023-07-24
- Completion
- 2023-07-24
Countries
- Greece
- Slovenia
Study Locations
More Related Trials
-
Dietary Sodium Restriction in Hemodialysis Patients
NCT01896882 ·Status: UNKNOWN ·Phase: NA
-
Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
NCT02145260 ·Status: COMPLETED ·Phase: NA
-
Haemodialysis Salt Reduction Study
NCT00141609 ·Status: COMPLETED ·Phase: NA
-
Steroids on Intra-dialytic Hypotension
NCT03465007 ·Status: COMPLETED ·Phase: NA
-
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
NCT01687699 ·Status: COMPLETED ·Phase: PHASE4
-
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114 ·Status: TERMINATED ·Phase: PHASE3
-
Is Hemodialysis Associated With Cardiac Markers Change?
NCT04929366 ·Status: COMPLETED ·Phase: NA
-
Effects of Spironolactone in Dialysis
NCT01128101 ·Status: UNKNOWN ·Phase: PHASE4
-
Spironolactone Safety in Dialysis Patients
NCT00328809 ·Status: WITHDRAWN ·Phase: PHASE4
-
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
NCT02778516 ·Status: COMPLETED ·Phase: NA
-
Loop Diuretics in Chronic Kidney Disease
NCT00478543 ·Status: COMPLETED ·Phase: PHASE4
-
Dialysate Sodium Individualization in Hemodialysis
NCT00259714 ·Status: TERMINATED ·Phase: PHASE1
-
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
NCT01848639 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
NCT00530595 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension
NCT01862497 ·Status: COMPLETED
-
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
NCT00865501 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
NCT03329443 ·Status: COMPLETED ·Phase: PHASE2
-
SASH: Sodium Accumulation Study In Haemodialysis
NCT05128188 ·Status: COMPLETED
-
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis
NCT03327909 ·Status: COMPLETED ·Phase: NA
-
Cardiovascular Evaluation of Adult PHA 1 Patients
NCT00646828 ·Status: COMPLETED
-
Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
NCT01172431 ·Status: COMPLETED ·Phase: PHASE4
-
Double Blind Crossover Comparison of Diuretics in the Young
NCT00429897 ·Status: UNKNOWN ·Phase: NA
-
Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
NCT01247090 ·Status: COMPLETED ·Phase: PHASE2
-
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
NCT02040441 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
NCT01691053 ·Status: COMPLETED ·Phase: PHASE2